The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

Sam Butterworth; Darren A E Cross; M Raymond V Finlay; Richard A Ward; Michael J Waring

doi:10.1039/c7md90012k

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.

Authors

Sam Butterworth¹, Darren A E Cross¹, M Raymond V Finlay¹, Richard A Ward¹, Michael J Waring¹

Affiliation

¹ AstraZeneca , Darwin Building , 310 Cambridge Science Park , Milton Road , Cambridge , CB4 0WG , UK . Email: ray.finlay@astrazeneca.com ; Email: richard.a.ward@astrazeneca.com.

Abstract

The winners of the Malcolm Campbell Memorial Prize for 2017 discuss the structure-guided discovery of Osimertinib and the difficulties associated with discovering a new drug.

Publication types

Editorial